Objective: To ascertain the incidence of metabolic syndrome among individuals affected by chronic plaque psoriasis. Place and Duration of Study: This was a cross-sectional study conducted at Shaikh Zayed Hospital, Lahore from August 2022, to January 2022.. MATERIAL AND METHODS: The study's sample size was determined to be 175, and a non-probability consecutive sampling method was employed to select participants. Inclusion criteria encompassed individuals of both genders aged 18 to 30 years with confirmed cases of Psoriasis persisting for at least one year. Exclusion criteria involved individuals with other skin disorders linked to metabolic syndrome, those already taking medications known to induce hyperglycemia, dyslipidemia, or hypertension, and those who declined to participate in the study. Demographic data, including age, blood pressure, total cholesterol, and fasting blood sugar, were recorded using predefined forms. The data was analyzed using SPSS (Registered) Version 22. RESULTS: The mean age of the group is approximately 35.11 years with a standard deviation of 6.22. Age-wise, 25.7% of the individuals are between 20-30 years old, while the majority, 74.3%, fall into the 31-60 years age group. In terms of gender, 56% are male, and 44% are female. There were 21 smokers (39.62%) among those with MS, and 32 (26.23%) among those without MS. Among patients with MS, 14 (26.42%) were alcoholic, while 25 (20.49%) were alcoholic among those without MS. In the group with MS, 73.58% had a PASI score of 10 or higher, while in the group without MS, 51.64% had a PASI score of 10 or higher. CONCLUSION: These discoveries should motivate healthcare professionals to perform routine screenings for metabolic disorders in psoriasis patients, particularly in cases of severe disease. This proactive approach is crucial in facilitating early diagnosis and appropriate treatment, and it underscores the elevated clinical suspicion required when psoriasis and metabolic syndrome coexist.